New research suggests the experimental drug Setanaxib can protect the heart in Duchenne muscular dystrophy (DMD). The study, published in Molecular Therapy, tested Setanaxib in two preclinical models of DMD and found that the treatment preserved cardiac function, limited heart enlargement and reduced tissue scarring. The results also highlight the enzyme NOX4 as a potential therapeutic target for cardiomyopathy, the serious form of heart disease often linked to DMD.
The study was led by Da-Zhi Wang, professor at the University of South Florida Health Morsani College of Medicine and director of the Center for Regenerative Medicine at the USF Health Heart Institute. The team included John Mably, associate professor, Gabriela Diniz, assistant professor, and outside collaborators. Wang noted that, despite progress in gene replacement therapies, DMD remains a devastating disease and that better understanding of its progression is urgently needed.
Setanaxib is designed to limit oxidative stress by targeting NOX1 and NOX4, enzymes that produce highly reactive molecules inside cells. At high levels these molecules cause inflammation and fibrosis. In the study Setanaxib reduced inflammation and fibrosis, lowered activity of genes associated with cardiomyopathy, and helped the heart keep its ability to pump blood. Mably noted that Nox4 inhibitors have already been tested in clinical trials for lung fibrosis and kidney and liver disease, and the team hopes for trials in DMD patients. Diniz said the work shows how basic biomedical science can help understand disease and improve care.
Difficult words
- enzyme — protein in cells that speeds chemical reactionsenzymes
- oxidative stress — cell damage caused by reactive oxygen molecules
- fibrosis — formation of excess scar tissue in organs
- cardiomyopathy — disease of the heart muscle reducing its function
- preclinical — tested in laboratory models before human trials
- preserve — keep something in its original state or conditionpreserved
- inflammation — body reaction that causes redness, swelling, pain
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- Why might targeting NOX4 be a promising approach for cardiomyopathy linked to DMD? Give reasons from the article.
- What steps and challenges do you think are needed before Setanaxib can be tested in DMD patients? Use details from the text.
Related articles
After-work invitations can help some employees but harm others
New research shows after-work invitations often make socially confident employees feel connected, while shy workers can feel pressure and anxiety. Authors advise people to know their limits and for coworkers to think before inviting.
New device measures blood viscosity in real time
Researchers at the University of Missouri created a non-invasive device that monitors blood viscosity and density in real time using ultrasound and software. It can read blood without drawing samples and may help in diseases like sickle cell.
Sudan turns to AI as health system struggles
Sudan’s health system is under severe strain after an almost two‑year civil war. A senior health official says the country is using artificial intelligence to help provide care where normal services no longer reach, while shortages and attacks worsen the crisis.
